Novartis Sclerosis Drug Patent Gets Axed In AIA Review
In a rare win for generic-drug makers contesting a branded drug patent, the Patent Trial and Appeal Board ruled Thursday that a patent covering Novartis AG's multiple sclerosis treatment Gilenya is...To view the full article, register now.
Already a subscriber? Click here to view full article